Pinkus Tober-Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pinkus Tober-Lau has a total of 430 co-authors. Here are the top co-authors by number of shared publications:
- Florian Kurth
Department of Infectious Diseases and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
29 shared publications - Leif Erik Sander
Department of Infectious Diseases, Respiratory, and Critical Care Medicine, Charite University Medical Center Berlin, Berlin, Germany
14 shared publications - David Hillus
Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin
11 shared publications - Florian Klein
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne
9 shared publications Leif Erik Sander
Berlin Institute of Health, Berlin, Germany
9 shared publications- Markus Ralser
Department of Biochemistry, Charité – Universitätsmedizin Berlin, Berlin, Germany
9 shared publications
Latest Publications
- 16 November 2026
- Published by Elsevier in Journal of Clinical Virology
- Vol. 187
Evaluation of published Filovirus RT-PCR assays for the detection of Bundibugyo virus, 2026
- 16 November 2026
- Published by Elsevier in Journal of Clinical Virology
- Vol. 187
Evaluation of published Filovirus RT-PCR assays for the detection of Bundibugyo virus, 2026
- Open Access
- 24 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3606-3611
Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children
- 24 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3606-3611
Open AccessPost-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children
- Open Access
- 24 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3600-3605
A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir
- 24 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3600-3605
Open AccessA case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir
- Open Access
Anti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B
Chronic infection with hepatitis B virus (HBV) is characterized by persistent expression of hepatitis B surface antigen (HBsAg), which is associated with profound immune tolerance. Although nucleos(t)ide analogue therapy effectively suppresses viral replication, it neither eliminates HBV nor reverses virus-specific immune dysfunction. Here, we report the results of two parallel first-in-human, dose-escalation studies evaluating a single infusion of mAb19-LS, a long-acting IgG1 monoclonal antibody targeting HBsAg, in individuals with chronic HBV infection receiving nucleos(t)ide analogue therapy. mAb19-LS was generally safe and well tolerated and induced a mean 11-fold increase in antigen clearance. The magnitude and duration of HBsAg suppression were dependent on both baseline antigen levels and mAb19-LS dose, with suppression maintained for more than 36 weeks in individuals receiving the highest dose. Reduction of circulating HBsAg was associated with uptake of HBsAg–IgG immune complexes by monocytes and dendritic cells and inflammatory reprogramming of these antigen-presenting cells. Notably, proliferation of both CD4 + and CD8 + T cells, as well as interferon-γ and TNF-α production in response to HBV antigens, were significantly increased 24 weeks after infusion. Together, these findings demonstrate that mAb19-LS is generally safe and effectively accelerates HBsAg clearance while activating antigen presenting cells and enhancing antiviral T cell responses.
Open AccessAnti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B
Chronic infection with hepatitis B virus (HBV) is characterized by persistent expression of hepatitis B surface antigen (HBsAg), which is associated with profound immune tolerance. Although nucleos(t)ide analogue therapy effectively suppresses viral replication, it neither eliminates HBV nor reverses virus-specific immune dysfunction. Here, we report the results of two parallel first-in-human, dose-escalation studies evaluating a single infusion of mAb19-LS, a long-acting IgG1 monoclonal antibody targeting HBsAg, in individuals with chronic HBV infection receiving nucleos(t)ide analogue therapy. mAb19-LS was generally safe and well tolerated and induced a mean 11-fold increase in antigen clearance. The magnitude and duration of HBsAg suppression were dependent on both baseline antigen levels and mAb19-LS dose, with suppression maintained for more than 36 weeks in individuals receiving the highest dose. Reduction of circulating HBsAg was associated with uptake of HBsAg–IgG immune complexes by monocytes and dendritic cells and inflammatory reprogramming of these antigen-presenting cells. Notably, proliferation of both CD4 + and CD8 + T cells, as well as interferon-γ and TNF-α production in response to HBV antigens, were significantly increased 24 weeks after infusion. Together, these findings demonstrate that mAb19-LS is generally safe and effectively accelerates HBsAg clearance while activating antigen presenting cells and enhancing antiviral T cell responses.
- Open Access
- 22 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Cross-platform clinical proteomics using the Charité open standard for plasma proteomics (OSPP)
The role of plasma and serum proteomics in characterizing human disease, identifying biomarkers, and advancing diagnostic technologies is rapidly increasing. However, there is an ongoing need to improve proteomic workflows in terms of accuracy, reproducibility, and cost-effectiveness, and to achieve cross-platform transferability. Based on large serum and plasma proteome studies, we generate the Charité Open Peptide Standard for Plasma Proteomics (OSPP), an open, versatile peptide internal standard for targeted and untargeted mass spectrometry-based proteomic studies. The OSPP includes 211 concentration-matched stable-isotope-labeled peptides selected for consistent quantification across a large number of plasma and serum proteome studies, and synthetic accessibility. We show they are consistently quantified across serum and EDTA, citrate, and heparin plasma using multiple LC-MS platforms. Despite being selected for technical parameters, the OSPP peptides represent proteins that function in a wide range of biological processes, are used in routine clinical tests, or are targets of FDA-approved drugs, making OSPP able to serve as an expandable clinical marker panel. We demonstrate the utility of OSPP in a COVID-19 inpatient cohort study for improving analytical performances, for cross-platform alignment of proteomic data, disease stratification, and biomarker discovery.
- 22 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessCross-platform clinical proteomics using the Charité open standard for plasma proteomics (OSPP)
The role of plasma and serum proteomics in characterizing human disease, identifying biomarkers, and advancing diagnostic technologies is rapidly increasing. However, there is an ongoing need to improve proteomic workflows in terms of accuracy, reproducibility, and cost-effectiveness, and to achieve cross-platform transferability. Based on large serum and plasma proteome studies, we generate the Charité Open Peptide Standard for Plasma Proteomics (OSPP), an open, versatile peptide internal standard for targeted and untargeted mass spectrometry-based proteomic studies. The OSPP includes 211 concentration-matched stable-isotope-labeled peptides selected for consistent quantification across a large number of plasma and serum proteome studies, and synthetic accessibility. We show they are consistently quantified across serum and EDTA, citrate, and heparin plasma using multiple LC-MS platforms. Despite being selected for technical parameters, the OSPP peptides represent proteins that function in a wide range of biological processes, are used in routine clinical tests, or are targets of FDA-approved drugs, making OSPP able to serve as an expandable clinical marker panel. We demonstrate the utility of OSPP in a COVID-19 inpatient cohort study for improving analytical performances, for cross-platform alignment of proteomic data, disease stratification, and biomarker discovery.
- Open Access
- 28 July 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (7)
Non-antifungal medications administered during fungal infections drive drug tolerance and resistance in Candida albicans
Introduction. Fungal infections are increasingly concerning, particularly in immunocompromised patients. These patients often suffer from comorbidities and receive multiple, non-antifungal medications. Gap Statement. The effects of these co-administered medications on fungal cells – and their potential to influence antifungal drug efficacy – are poorly understood. Aim. This study investigates non-antifungal medications commonly administered in parallel to antifungals and evaluates their impact on fungal susceptibility. Methodology. We systematically reviewed clinical guidelines to identify non-antifungal medications frequently co-prescribed with antifungals. Focusing on Candida albicans, the most prevalent fungal pathogen, we examined whether the presence of these drugs influences antifungal responses of C. albicans. First, we tested the selected compounds together with antifungals in combination assays. Interactions were then characterized using checkerboard assays, and the impact on antifungal resistance and tolerance was evaluated through disc diffusion assays. To further explore these effects in vivo, the influence of selected antagonistic interactions on treatment efficacy was assessed using a Galleria mellonella model of disseminated candidiasis. Results. From 119 medications used to manage 40 conditions linked to a high risk of fungal infections, we identified 34 compounds that altered the effectiveness of the antifungals fluconazole (FLC) and/or anidulafungin. Most of these compounds reduced or antagonized antifungal efficacy, often due to increased resistance or tolerance. Validation in a G. mellonella infection model confirmed that compounds antagonistic to FLC, including loperamide, estradiol and levothyroxine, interfere with antifungal treatment efficacy in this in vivo model. Conclusion. Our findings highlight that medications frequently used by patients at risk for fungal infections can inadvertently increase fungal pathogen drug tolerance or resistance. We suggest that drugs targeting non-fungal conditions yet affecting fungal pathogens might represent an underestimated factor contributing to rising antifungal resistance and tolerance.
- 28 July 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (7)
Open AccessNon-antifungal medications administered during fungal infections drive drug tolerance and resistance in Candida albicans
Introduction. Fungal infections are increasingly concerning, particularly in immunocompromised patients. These patients often suffer from comorbidities and receive multiple, non-antifungal medications. Gap Statement. The effects of these co-administered medications on fungal cells – and their potential to influence antifungal drug efficacy – are poorly understood. Aim. This study investigates non-antifungal medications commonly administered in parallel to antifungals and evaluates their impact on fungal susceptibility. Methodology. We systematically reviewed clinical guidelines to identify non-antifungal medications frequently co-prescribed with antifungals. Focusing on Candida albicans, the most prevalent fungal pathogen, we examined whether the presence of these drugs influences antifungal responses of C. albicans. First, we tested the selected compounds together with antifungals in combination assays. Interactions were then characterized using checkerboard assays, and the impact on antifungal resistance and tolerance was evaluated through disc diffusion assays. To further explore these effects in vivo, the influence of selected antagonistic interactions on treatment efficacy was assessed using a Galleria mellonella model of disseminated candidiasis. Results. From 119 medications used to manage 40 conditions linked to a high risk of fungal infections, we identified 34 compounds that altered the effectiveness of the antifungals fluconazole (FLC) and/or anidulafungin. Most of these compounds reduced or antagonized antifungal efficacy, often due to increased resistance or tolerance. Validation in a G. mellonella infection model confirmed that compounds antagonistic to FLC, including loperamide, estradiol and levothyroxine, interfere with antifungal treatment efficacy in this in vivo model. Conclusion. Our findings highlight that medications frequently used by patients at risk for fungal infections can inadvertently increase fungal pathogen drug tolerance or resistance. We suggest that drugs targeting non-fungal conditions yet affecting fungal pathogens might represent an underestimated factor contributing to rising antifungal resistance and tolerance.
- Open Access
- 17 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8)
Comparative Analysis of Initial Full Blood Count Parameters in Adults Infected With Plasmodium falciparum for Classification of Disease Severity and Previous Exposure Across Endemic (Gabon) and Nonendemic (Germany) Settings
Background: The clinical presentation of individuals infected with Plasmodium falciparum is exceptionally diverse, ranging from asymptomatic parasitemia to life-threatening disease. Frequent previous exposure to Plasmodium spp results in partial protection from severe disease; however, this protection wanes in individuals emigrating from holoendemic regions, and there are currently no reliable biomarkers that accurately indicate this semi-immunity. Methods: Data were analyzed from 1392 adults infected with P falciparum in Gabon and Germany. Full blood count parameters and ratios were evaluated individually and as a combined ensemble-based machine learning classifier to predict disease severity, ranging from asymptomatic infection to severe malaria. As a secondary objective, the influence of previous exposure to Plasmodium spp was assessed. Results: Comparing asymptomatic parasitemia with uncomplicated malaria in Gabonese and comparing uncomplicated with severe malaria in German patients revealed significantly lower platelet counts (218 vs 150 ×103/µL, P < .0001; 85 vs 40 ×103/µL, P < .0001, respectively) and higher neutrophil counts (2.32 vs 2.57 ×103/µL, P = .0037; 3.08 vs 4.49 ×103/µL, P < .0001) in those with greater infection severity. The machine learning classifier outperformed single parameters in differentiating infection severity in both comparisons (area under the receiver operating characteristic curve, 0.94 and 0.84). Lymphocyte and monocyte counts showed a pattern that follows the level of previous malaria exposure, with lower cell counts in naive vs previously exposed patients, regardless of infection severity. Conclusions: The value of simple full blood count parameters for classification of P falciparum infection severity and previous exposure is considerable. The accuracy can be increased by integrating individual parameters into a joint machine learning model.
- 17 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8)
Open AccessComparative Analysis of Initial Full Blood Count Parameters in Adults Infected With Plasmodium falciparum for Classification of Disease Severity and Previous Exposure Across Endemic (Gabon) and Nonendemic (Germany) Settings
Background: The clinical presentation of individuals infected with Plasmodium falciparum is exceptionally diverse, ranging from asymptomatic parasitemia to life-threatening disease. Frequent previous exposure to Plasmodium spp results in partial protection from severe disease; however, this protection wanes in individuals emigrating from holoendemic regions, and there are currently no reliable biomarkers that accurately indicate this semi-immunity. Methods: Data were analyzed from 1392 adults infected with P falciparum in Gabon and Germany. Full blood count parameters and ratios were evaluated individually and as a combined ensemble-based machine learning classifier to predict disease severity, ranging from asymptomatic infection to severe malaria. As a secondary objective, the influence of previous exposure to Plasmodium spp was assessed. Results: Comparing asymptomatic parasitemia with uncomplicated malaria in Gabonese and comparing uncomplicated with severe malaria in German patients revealed significantly lower platelet counts (218 vs 150 ×103/µL, P < .0001; 85 vs 40 ×103/µL, P < .0001, respectively) and higher neutrophil counts (2.32 vs 2.57 ×103/µL, P = .0037; 3.08 vs 4.49 ×103/µL, P < .0001) in those with greater infection severity. The machine learning classifier outperformed single parameters in differentiating infection severity in both comparisons (area under the receiver operating characteristic curve, 0.94 and 0.84). Lymphocyte and monocyte counts showed a pattern that follows the level of previous malaria exposure, with lower cell counts in naive vs previously exposed patients, regardless of infection severity. Conclusions: The value of simple full blood count parameters for classification of P falciparum infection severity and previous exposure is considerable. The accuracy can be increased by integrating individual parameters into a joint machine learning model.
- Open Access
- 17 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e383-e392
Plasma Proteomics Reveals Distinct Signatures in Occult and Microfilaremic Loa loa Infections
Background: Loiasis, caused by the filarial nematode Loa loa, imposes a significant disease burden in endemic regions in West and Central Africa. Manifestations include adult worms in soft tissue (e.g., the conjunctiva of the eye) and microfilaria in peripheral blood, with clinical presentations ranging from asymptomatic infections to life-threatening organ involvement. Diagnosis remains challenging due to variable microfilaria counts, frequent amicrofilaremic occult infections, and unreliable serological tests. The untargeted plasma proteome reflects broad (patho-)physiological responses, providing valuable insights into the host and disease. Methods: Applying high-throughput plasma proteomics, we investigated the host responses of 274 patients with different L. loa disease states, including occult loiasis (n = 148), microfilaremia (n = 42), or both (n = 84), compared to 136 L. loa–negative controls. Differentially abundant proteins between L. loa–infected individuals and negative controls were validated using targeted proteomics. Results: Five proteins (IGHG3, IGHG4, ACTBL2, LCP1, and IGLV9-49) were elevated in infected individuals compared to healthy controls. IGHG3, IGHG4, ACTB, and LCP1 increased from L. loa negative over individuals with history of eye worm migration to microfilaremic patients, indicating a comparatively pronounced proteomic host response to microfilaria in the blood. Sixty-three proteins differed depending on self-reported symptoms. The proteomic signatures enabled accurate classification of individuals with occult loiasis (area under the receiver operating characteristic curve [AUROC] = 0.73) and microfilaremia (AUROC = 0.84) by a random forest machine learning model. Conclusions: Overall, infection with Loa loa alters the host plasma proteome, exhibiting distinct host responses in different infection states and allowing for molecular disease classification of this highly neglected parasitic disease.
- 17 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e383-e392
Open AccessPlasma Proteomics Reveals Distinct Signatures in Occult and Microfilaremic Loa loa Infections
Background: Loiasis, caused by the filarial nematode Loa loa, imposes a significant disease burden in endemic regions in West and Central Africa. Manifestations include adult worms in soft tissue (e.g., the conjunctiva of the eye) and microfilaria in peripheral blood, with clinical presentations ranging from asymptomatic infections to life-threatening organ involvement. Diagnosis remains challenging due to variable microfilaria counts, frequent amicrofilaremic occult infections, and unreliable serological tests. The untargeted plasma proteome reflects broad (patho-)physiological responses, providing valuable insights into the host and disease. Methods: Applying high-throughput plasma proteomics, we investigated the host responses of 274 patients with different L. loa disease states, including occult loiasis (n = 148), microfilaremia (n = 42), or both (n = 84), compared to 136 L. loa–negative controls. Differentially abundant proteins between L. loa–infected individuals and negative controls were validated using targeted proteomics. Results: Five proteins (IGHG3, IGHG4, ACTBL2, LCP1, and IGLV9-49) were elevated in infected individuals compared to healthy controls. IGHG3, IGHG4, ACTB, and LCP1 increased from L. loa negative over individuals with history of eye worm migration to microfilaremic patients, indicating a comparatively pronounced proteomic host response to microfilaria in the blood. Sixty-three proteins differed depending on self-reported symptoms. The proteomic signatures enabled accurate classification of individuals with occult loiasis (area under the receiver operating characteristic curve [AUROC] = 0.73) and microfilaremia (AUROC = 0.84) by a random forest machine learning model. Conclusions: Overall, infection with Loa loa alters the host plasma proteome, exhibiting distinct host responses in different infection states and allowing for molecular disease classification of this highly neglected parasitic disease.
- 12 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6752) , eadq6741
A metabolite-based resistance mechanism against malaria
Jaundice is a common presentation of Plasmodium falciparum malaria, which arises from the accumulation of circulating bilirubin. It is not understood whether it represents an adaptive or maladaptive response to Plasmodium spp. infection. We found that asymptomatic P. falciparum infection in humans was associated with a higher ratio of unconjugated over conjugated bilirubin and parasite burden compared with symptomatic malaria. Genetic suppression of bilirubin synthesis by biliverdin reductase A (BVRA) increased parasite virulence and malaria mortality in mice. Accumulation of unconjugated bilirubin in plasma, through genetic inhibition of hepatic conjugation by UDP glucuronosyltransferase family 1 member A1 (UGT1A1), was protective against malaria in mice. Unconjugated bilirubin inhibited P. falciparum proliferation in red blood cells by a mechanism that suppressed mitochondrial pyrimidine synthesis. Moreover, unconjugated bilirubin inhibited hemozoin crystallization and compromised the parasite’s food vacuole. Hence, jaundice appears to represent a metabolic response to Plasmodium spp. infection that limits malaria severity.
- 12 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6752) , eadq6741
A metabolite-based resistance mechanism against malaria
Jaundice is a common presentation of Plasmodium falciparum malaria, which arises from the accumulation of circulating bilirubin. It is not understood whether it represents an adaptive or maladaptive response to Plasmodium spp. infection. We found that asymptomatic P. falciparum infection in humans was associated with a higher ratio of unconjugated over conjugated bilirubin and parasite burden compared with symptomatic malaria. Genetic suppression of bilirubin synthesis by biliverdin reductase A (BVRA) increased parasite virulence and malaria mortality in mice. Accumulation of unconjugated bilirubin in plasma, through genetic inhibition of hepatic conjugation by UDP glucuronosyltransferase family 1 member A1 (UGT1A1), was protective against malaria in mice. Unconjugated bilirubin inhibited P. falciparum proliferation in red blood cells by a mechanism that suppressed mitochondrial pyrimidine synthesis. Moreover, unconjugated bilirubin inhibited hemozoin crystallization and compromised the parasite’s food vacuole. Hence, jaundice appears to represent a metabolic response to Plasmodium spp. infection that limits malaria severity.
- 30 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Severe imported Plasmodium falciparum malaria with hyperparasitaemia: evaluation of determinants of critical disease in adult returning travellers
Background: Severe Plasmodium falciparum (P.f.) malaria remains a major health threat for travellers. World Health Organization (WHO) defines criteria for severe malaria, including hyperparasitaemia ≥10% infected red blood cells (iRBCs), as major risk factors for adverse outcome. Additionally, WHO recognizes ‘uncomplicated hyperparasitaemia’ with 4–10% iRBC, a parasite density usually defining severe malaria outside endemic areas. Overall, the role of hyperparasitaemia as an independent risk factor in imported severe malaria is unclear, with most data predating the artemisinin era. Methods: We retrospectively analysed adult in-patients with hyperparasitaemia (≥4% iRBC) and/or severe P.f. malaria according to WHO criteria who received artemisinin-based treatment at two German university hospitals 2013–2023, to assess the risk for critical disease with need for organ replacement therapy or vasopressors. Based on multivariable nominal logistic regression, we developed a scoring system to identify patients with critical disease and validated it on an independent cohort. Results: Of 168 patients, 33 (20%) developed critical disease, all of whom presented with at least one WHO criterion other than hyperparasitaemia. Of 72 patients with isolated hyperparasitaemia, none developed critical disease. Hyperparasitaemia was no independent risk factor for critical disease in logistic regression (adjusted odds ratio (aOR) 0.85 95%CI 0.23–3.12), in contrast to creatinine >3 mg/dl (aOR 6.74 95%CI 1.06–42.75), oligo-/anuria (aOR 5.94 95%CI 1.27–27.82), lactate ≥5 mmol/l (aOR 8.16 95%CI 8.16–35.03), confusion (aOR 4.07 95%CI 1.39–11.94) and circulatory shock and respiratory failure, which are inherently critical conditions. The risk score identified all 33 patients with and 131/135 (97.0%) without critical disease (AUC = 0.99; sensitivity: 100%; specificity: 97.0%). In the validation cohort, all eight patients with critical disease and 39/44 (89%) without were correctly identified. Conclusion: Isolated hyperparasitaemia was no independent risk factor for critical disease in this patient cohort treated with artemisinins, suggesting that such patients can be managed outside intensive care units.
- 30 May 2025
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 32 (6)
Severe imported Plasmodium falciparum malaria with hyperparasitaemia: evaluation of determinants of critical disease in adult returning travellers
Background: Severe Plasmodium falciparum (P.f.) malaria remains a major health threat for travellers. World Health Organization (WHO) defines criteria for severe malaria, including hyperparasitaemia ≥10% infected red blood cells (iRBCs), as major risk factors for adverse outcome. Additionally, WHO recognizes ‘uncomplicated hyperparasitaemia’ with 4–10% iRBC, a parasite density usually defining severe malaria outside endemic areas. Overall, the role of hyperparasitaemia as an independent risk factor in imported severe malaria is unclear, with most data predating the artemisinin era. Methods: We retrospectively analysed adult in-patients with hyperparasitaemia (≥4% iRBC) and/or severe P.f. malaria according to WHO criteria who received artemisinin-based treatment at two German university hospitals 2013–2023, to assess the risk for critical disease with need for organ replacement therapy or vasopressors. Based on multivariable nominal logistic regression, we developed a scoring system to identify patients with critical disease and validated it on an independent cohort. Results: Of 168 patients, 33 (20%) developed critical disease, all of whom presented with at least one WHO criterion other than hyperparasitaemia. Of 72 patients with isolated hyperparasitaemia, none developed critical disease. Hyperparasitaemia was no independent risk factor for critical disease in logistic regression (adjusted odds ratio (aOR) 0.85 95%CI 0.23–3.12), in contrast to creatinine >3 mg/dl (aOR 6.74 95%CI 1.06–42.75), oligo-/anuria (aOR 5.94 95%CI 1.27–27.82), lactate ≥5 mmol/l (aOR 8.16 95%CI 8.16–35.03), confusion (aOR 4.07 95%CI 1.39–11.94) and circulatory shock and respiratory failure, which are inherently critical conditions. The risk score identified all 33 patients with and 131/135 (97.0%) without critical disease (AUC = 0.99; sensitivity: 100%; specificity: 97.0%). In the validation cohort, all eight patients with critical disease and 39/44 (89%) without were correctly identified. Conclusion: Isolated hyperparasitaemia was no independent risk factor for critical disease in this patient cohort treated with artemisinins, suggesting that such patients can be managed outside intensive care units.